The DOI matches its Crossref record; 33 of the 34 references it cites were found in a registry or an index.
High Plasma Levels of Factor VIII and the Risk of Recurrent Venous Thromboembolism
Open accessAbstract
BACKGROUND: A high plasma level of factor VIII is a risk factor for venous thromboembolism. We evaluated the risk of a recurrence of thrombosis after an initial episode of spontaneous venous thromboembolism among patients with high plasma levels of factor VIII. METHODS: We studied 360 patients for an average follow-up period of 30 months after a first episode of venous thromboembolism and discontinuation of oral anticoagulants. Patients who had recurrent or secondary venous thromboembolism, a congenital deficiency of an anticoagulant, the lupus anticoagulant, hyperhomocysteinemia, cancer, or a requirement for long-term treatment with antithrombotic drugs or who were pregnant were excluded. The end point was objectively documented, symptomatic recurrent venous thromboembolism. RESULTS: Recurrent venous thromboembolism developed in 38 of the 360 patients (10.6 percent). Patients with recurrence had higher mean (+/-SD) plasma levels of factor VIII than those without recurrence (182+/-66 vs. 157+/-54 IU per deciliter, P=0.009). The relative risk of recurrent venous thrombosis was 1.08 (95 percent confidence interval, 1.04 to 1.12; P<0.001) for each increase of 10 IU per deciliter in the plasma level of factor VIII. Among patients with a factor VIII level above the 90th percentile of the values in the study population, the likelihood of recurrence at two years was 37 percent, as compared with a 5 percent likelihood among patients with lower levels (P<0.001). Among patients with plasma factor VIII levels above the 90th percentile, as compared with those with lower levels, the overall relative risk of recurrence was 6.7 (95 percent confidence interval, 3.0 to 14.8) after adjustment for age, sex, the presence or absence of factor V Leiden or the G20210A prothrombin mutation, and the duration of oral anticoagulation. CONCLUSIONS: Patients with a high plasma level of factor VIII have an increased risk of recurrent venous thromboembolism.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Potentially targeting FVIII/FIX:C, >10%–150% of normal postgene transfer is supported by both the aforementioned prothrombotic risks associated with supraphysiologic FVIII/FIX:C206, 207, 208 and available HA natural history data that demonstrate that FVIII:C of ≥12% of normal (by OSA) is adequate to prevent spontaneous joint bleeding.210”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [208]
In the citing paper
“Epidemiological studies have outlined that supraphysiologic FIX:C is a modest independent risk-factor venous thrombosis (odds ratio [OR] 1.8−4.0) relative to supraphysiologic FVIII (OR 8.8−21.3).206, 207, 208”
From Current clinical applications of in vivo gene therapy with AAVs (2021) · cites this paper as [208]
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
Mutation in blood coagulation factor V associated with resistance to activated protein C
Bertina, R. M., Koeleman, B. P. C., Koster, T., Rosendaal, F. R., Dirven, R. J., de Ronde, H., van der Velden, P. A., & Reitsma, P. H. (1994) · Nature · doi:10.1038/369064a0 · Cited by 3,783
Poort, Sr., Rosendaal, F., Reitsma, P., & Bertina, R. (1996) · Blood · doi:10.1182/blood.v88.10.3698.bloodjournal88103698 · Cited by 3,079
The Long-Term Clinical Course of Acute Deep Venous Thrombosis
Prandoni, P., Lensing, A. W. A., Cogo, A., Cuppini, S., Villalta, S., Carta, M., Cattelan, A. M., Polistena, P., Bernardi, E., & Prins, M. H. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-125-1-199607010-00001 · Cited by 2,109
The management of thrombosis in the antiphospholipid-antibody syndrome
Khamashta, M. A., Cuadrado, M. J., Mujic, F., Taub, N. A., Hunt, B. J., & Hughes, G. R. V. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504133321504 · Cited by 1,450
Palareti, G., Leali, N., Coccheri, S., Poggi, M., Manotti, C., D'Angelo, A., Pengo, V., Erba, N., Moia, M., Ciavarella, N., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)01109-9 · Cited by 1,333
Brandt, J. T., Triplett, D. A., Alving, B. M., & Scharrer, I. (1995) · PubMed · Cited by 1,164
Hemorrhagic Complications of Anticoagulant Treatment
Levine, M. N., Raskob, G., Landefeld, S., & Kearon, C. (2001) · Chest · doi:10.1378/chest.119.1_suppl.108s · Cited by 1,134
Research works printed but not linked: 2
- 10.2307/2281868 · doi:10.2307/2281868 · Paper page
- Eichinger S, 1998, Thromb Haemost, 80, 566
Cited by
Risk Factors for Venous Thromboembolism
Anderson, F. A., & Spencer, F. A. (2003) · Circulation · doi:10.1161/01.cir.0000078469.07362.e6 · Cited by 1,652
Antithrombotic Therapy for Venous Thromboembolic Disease
Büller, H. R., Agnelli, G., Hull, R. D., Hyers, T. M., Prins, M. H., & Raskob, G. E. (2004) · Chest · doi:10.1378/chest.126.3_suppl.401s · Cited by 1,249
Natural History of Venous Thromboembolism
Kearon, C. (2003) · Circulation · doi:10.1161/01.cir.0000078464.82671.78 · Cited by 1,048
Genetic Susceptibility to Venous Thrombosis
Seligsohn, U., & Lubetsky, A. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104193441607 · Cited by 822
Epidemiology and Risk Factors for Venous Thrombosis
Cushman, M. (2007) · Seminars in Hematology · doi:10.1053/j.seminhematol.2007.02.004 · Cited by 755
Metadata
- Authors
- Kyrle, P. A., Minar, E., Hirschl, M., Bialonczyk, C., Stain, M., Schneider, B., Weltermann, A., Speiser, W., Lechner, K., & Eichinger, S.
- Affiliations
- Medical University of Vienna (AT)
- Hanusch Hospital (AT)
- Wilhelminen Hospital (AT)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2000-08-17
- Volume
- 343
- Issue
- 7
- Pages
- 457-462
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2337281790
- Cited by
- 763
- References
- 34
- Citations by year
- 2026: 10 · 2025: 19 · 2024: 17 · 2023: 20 · 2022: 19 · 2021: 23 · 2020: 28 · 2019: 19 · 2018: 18 · 2017: 20 · 2016: 20 · 2015: 27 · 2014: 28 · 2013: 32 · 2012: 36
- FWCI
- 26.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Keywords
- factor VIII, venous thromboembolism, recurrent thrombosis, hypercoagulability, thrombosis risk factors, factor V Leiden, prothrombin G20210A, oral anticoagulation
- MeSH terms
- Factor VIII, Female, Humans, Male, Middle Aged, Prospective Studies, Pulmonary Embolism, Recurrence, Risk, Risk Factors, Venous Thrombosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: High Plasma Levels of Factor VIII and the Risk of Recurrent Venous Thromboembolism. https://app.cochat.ai/papers/10.1056/nejm200008173430702
- The paper
- Kyrle, P. A., Minar, E., Hirschl, M., Bialonczyk, C., Stain, M., Schneider, B., Weltermann, A., Speiser, W., Lechner, K., & Eichinger, S. (2000). High Plasma Levels of Factor VIII and the Risk of Recurrent Venous Thromboembolism. New England Journal of Medicine. https://doi.org/10.1056/nejm200008173430702
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.